Vistagen Therapeutics, Inc. SEC filings VTGN
Vistagen Therapeutics, Inc. has 908 filings in SEC EDGAR's recent list, going back to Sep 11, 2007. Its latest annual report, Form 10-K, was filed on Jun 15, 2026 for the period ended Mar 31, 2026. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 30, 2026 (exit or restructuring costs, other events). The company's fiscal year ends on March 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B5 | Prospectus supplement | Jun 17, 2025 | — |
| S-8 | Employee stock plan registration | Jun 17, 2024 | — |
| S-3 | Shelf registration | Feb 13, 2024 | — |
| 424B5 | Prospectus supplement | Oct 3, 2023 | — |
| 424B5 | Prospectus supplement | Aug 8, 2023 | — |
| 424B5 | Prospectus supplement | Jun 30, 2023 | — |
| S-3/A | Form s-3/a | Mar 17, 2023 | — |
| S-3 | Shelf registration | Mar 2, 2023 | — |
| S-8 | Employee stock plan registration | Sep 24, 2021 | — |
| 424B5 | Prospectus supplement | May 14, 2021 | — |
| S-3 | Shelf registration | Mar 15, 2021 | — |
| 424B5 | Prospectus supplement | Dec 21, 2020 | — |
| FWP | Free writing prospectus | Dec 18, 2020 | — |
| 424B5 | Prospectus supplement | Dec 17, 2020 | — |
| 424B5 | Prospectus supplement | Aug 4, 2020 | — |
| 424B5 | Prospectus supplement | Jul 31, 2020 | — |
| 424B3 | Prospectus | May 15, 2020 | — |
| S-3/A | Primary document | May 11, 2020 | — |
| S-3 | Shelf registration | May 1, 2020 | — |
| 424B3 | Prospectus | Apr 15, 2020 | — |
| S-1/A | Amended registration statement | Apr 10, 2020 | — |
| S-1 | Registration statement | Mar 31, 2020 | — |
| 424B5 | Prospectus supplement | Jan 24, 2020 | — |
| S-3/A | Amendment no. 1 | Oct 4, 2019 | — |
| S-8 | Employee stock plan registration | Oct 1, 2019 | — |
| S-8 POS | Filing | Oct 1, 2019 | — |
| S-3 | Shelf registration | Sep 30, 2019 | — |
| 424B5 | Prospectus supplement | Feb 27, 2019 | — |
| 424B5 | Prospectus supplement | Feb 25, 2019 | — |
| S-8 | Employee stock plan registration | Mar 9, 2018 | — |
| 424B4 | Prospectus | Dec 12, 2017 | — |
| POS AM | Filing | Dec 11, 2017 | — |
| S-1/A | Amended registration statement | Dec 7, 2017 | — |
| S-1 | Registration statement | Oct 18, 2017 | — |
| 424B5 | Prospectus supplement | Aug 31, 2017 | — |
| S-3/A | Filing | May 11, 2017 | — |
| S-3/A | Amendment to form s-3 | Apr 4, 2017 | — |
| S-3 | Shelf registration | Jan 23, 2017 | — |
| 424B4 | Prospectus | May 12, 2016 | — |
| S-1/A | Amended registration statement | May 10, 2016 | — |
| S-1/A | Amended registration statement | May 5, 2016 | — |
| FWP | Free writing prospectus | Apr 15, 2016 | — |
| S-1/A | Amended registration statement | Apr 15, 2016 | — |
| S-1 | Registration statement | Mar 14, 2016 | — |
| S-8 | Employee stock plan registration | Dec 4, 2015 | — |
| 424B3 | Prospectus | Sep 1, 2015 | — |
| S-1/A | Amended registration statement | Aug 26, 2015 | — |
| S-1 | Registration statement | Jul 21, 2015 | — |
| 424B4 | Prospectus | Aug 28, 2014 | — |
| S-1/A | Amended registration statement | Aug 6, 2014 | — |
| S-1/A | Amended registration statement | Jul 29, 2014 | — |
| S-1/A | Amended registration statement | Jul 28, 2014 | — |
| S-1/A | Amended registration statement | Jul 7, 2014 | — |
| S-1/A | Amended registration statement | May 20, 2014 | — |
| S-1 | Registration statement | May 12, 2014 | — |
Showing 55 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VTGN (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- NV
- Headquarters
- South San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1411685
- Former names
- Excaliber Enterprises, Ltd. (until Jun 8, 2011)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.